Data on 10 social determinants of health (SDOH) were analyzed to determine their distribution among low-income patients hospitalized for heart failure (HF) at a safety-net hospital.
More emphasis needs to be placed on finding solutions to the social determinants of health (SDOH) that hinder care access for low-income patients living with heart failure (HF), according to research presented1 at last month’s American Society for Preventive Cardiology’s Congress on CVD Prevention, held in Arlington, Texas.
The patients (N = 118) in this study had been hospitalized for HF exacerbations at Parkland Memorial Hospital, a safety-net hospital in Dallas. Most (61.9%) of these participants were non-Hispanic Black; 20.3% were Hispanic; 15.3%, non-Hispanic White; and 2.5%, non-Hispanic other. Their mean (SD) age was 53.4 (10.5) years, 75.4% were male patients, and the median annual income was $13,200. HF with reduced ejection fraction (HFrEF) was prominent, with mean left ventricular rejection fraction (LVEF) being 30% (14%). A diagnosis of HFrEF is typically given when LVEF is 40% or below.2
“Association between SDOH and HF is well established,” the study authors wrote. “Distribution of SDOH amongst patients hospitalized for HF is unknown, especially at safety-net hospitals.”
They investigated these 10 SDOH domains: housing instability, financial health, food security, cost-related medication nonadherence, transportation barriers, social support, interpersonal violence, discrimination, health literacy, and health numeracy. Data on substance use disorder were also included where available. To be included in this analysis, all of the patients had to speak English or Spanish and they could not be in police custody or jail.
Overall, approximately half of the patients in this analysis (47.5%) reported at least 1 form of substance use disorder, and 63.1% reported living below 130% of the federal poverty limit. The top 3 most common SDOH were discrimination (87.3%), poor financial health (78.0%), and transportation barriers (67.8%).
Drilling down even further, the following were reported:
Food security was classified into 3 categories—high, low, and very low—with most respondents (44.9%) reporting they had a high level of food security. Just as many (43.2%) reported a very low level of food security, and 11.9% reported a low level of food insecurity.
When prevalence was analyzed by race, 5 areas of distinction emerged, highlighting differences:
Overall, most patients reported 3 or 7 SDOH (16.1% each) as affecting their HF care, followed by 15.25% reporting 6 SDOH; 14.41%, 5 SDOH; 12.71%, 4SDOH; 7.63%, 2 SDOH; 6.78%, 8 SDOH; 5.08%, 1 SDOH; 3.39%, 9 SDOH; and 0.85%, 10 SDOH.
“There is a substantial SDOH burden in safety-net, inpatient populations,” the study authors concluded. “Next steps should include targeting SDOH for their effects on HF outcomes.”
References
1. Lokesh N, Nagori A, Keshvani N, Ambarish P, Sumarsono. Social determinants in a low-income population with heart failure (HF). Presented at: ASPC Congress on CVD Prevention; July 21-23, 2023; Arlington, Texas. Poster 143.
2. What is ejection fraction ? (HFrEF and HFpEF). Heartfailurematters.org. Accessed August 14, 2023. https://www.heartfailurematters.org/understanding-heart-failure/what-is-ejection-fraction-hfref-and-hfpef/
3. Numeracy. CDC. Updated March 18, 2022. Accessed August 14, 2023. https://www.cdc.gov/healthliteracy/researchevaluate/numeracy.html#:~:text=In%20the%20context%20of%20health,about%20screening%20and%20treatment%20options
Leveraging AI and Community Health Workers to Boost Trial Access
January 4th 2025In this second part of our interview with Kasey Bond, MPH, NYU Langone Health, we discuss the contributions of community health workers to increasing clinical trial access and how technology—artificial intelligence (AI), in particular—can help to facilitate the process.
Read More
Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma
December 19th 2024Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
BeiGene’s Mehrdad Mobasher, MD, MPH, Discusses CLL Data, Pipeline Following ASH 2024
January 2nd 2025This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of Hematology Meeting and Exposition. After this article went to press, the company announced its ticker symbol on the Nasdaq will change today.
Read More